PluroGen Therapeutics, Inc. Announces Clinical Paper Reporting Success for PluroGel® PSSD Accepted for Publication

Posted on February 19, 2015 by - Uncategorized

Download PDF

2495 General Armistead Avenue ● Norristown, Pennsylvania 19403 ● USA ● Tel: +1 (610) 539-3670 ● Fax: +1 (610) 539-3831

Norristown, Pennsylvania, 21 August 2014

PluroGen Therapeutics, Inc., leading solutions for wound, burn and skin care with its advanced PluroGel® Biomaterial surfactant products, announced today that the authors of a clinical paper reporting successful results on patients using the Company’s PluroGel® PSSD Burn and Wound Dressing received notice that this paper has been accepted for publication by a leading wound journal.

Publication of this paper is a major milestone for PluroGen and PluroGel® PSSD Burn and Wound Dressing because it is the first scientifically peer-reviewed complete clinical study to be published in a journal.

“For PluroGel® PSSD Burn and Wound Dressing to have such a significant scientific support document is an important step forward and valuable asset” commented Neal Koller, President and CEO of PluroGen. “Once published, this article will be a valuable tool to support product use and sales and for obtaining product reimbursement from insurance companies and government payers”.

For Immediate Release
Contact: Neal Koller
President & CEO
+1 (610) 539-3670

US Patent Claims Allowed For PluroGen’s Nano-silver Antimicrobial Technology

Posted on February 19, 2015 by - Uncategorized

Download PDF

2495 General Armistead Avenue ● Norristown, Pennsylvania 19403 ● USA ● Tel: +1 (610) 539-3670 ● Fax: +1 (610) 539-3831

Norristown, Pennsylvania, 30 July 2014

PluroGen Therapeutics, Inc., leading solutions for wound, burn and skin care with its advanced PluroGel® Biomaterial surfactant products, announced today that it received notice from the United States Patent and Trademark Office (USPTO) that new patent claims will be allowed for its Nano-silver antimicrobial technology. PluroGen expects a new patent to issue.

The claims noted by the USPTO that will be allowed cover what the Company anticipates is a next generation antimicrobial technology to be used for products based on PluroGen’s patented Polysaccharide Natural Gel Technology and its patented advanced PluroGel® Biomaterial. Silver has long been used as an antimicrobial material. The advantage of Nano-silver is the silver particles are much smaller than typical silver products which provides much more silver surface area. This increased silver surface area is thought to have the benefit of more effective antimicrobial activity and the possibility of reduction of the amount of silver needed in a product.

“A new patent that will provide protection for a next generation antimicrobial technology will be an important new asset and addition to the Company’s intellectual property portfolio” commented Neal Koller, President and CEO of PluroGen.

For Immediate Release
Contact: Neal Koller
President & CEO
+1 (610) 539‐3670

PluroGen Therapeutics, Inc. Announces US Patent Claims Allowed For its Advanced PluroGel® Biomaterial

Posted on February 19, 2015 by - Uncategorized

Download PDF

2495 General Armistead Avenue ● Norristown, Pennsylvania 19403 ● USA ● Tel: +1 (610) 539-3670 ● Fax: +1 (610) 539-3831

Norristown, Pennsylvania 21 July 2014

PluroGen Therapeutics, Inc., leading solutions for wound, burn and skin care with its advanced PluroGel® Biomaterial surfactant products, announced today that it received notice from the United States Patent and Trademark Office (USPTO) that new patent claims will be allowed for its Advanced PluroGel® Biomaterial. PluroGen expects a new patent to issue.

The claims noted by the USPTO that will be allowed cover the special ability of the Company’s advanced PluroGel® Biomaterial to have a positive effect in preventing or dispersing biofilms in wounds. Biofilm establishment in a wound is thought to prevent wound healing. PluroGel’s ability prevent or disperse biofilms is a significant performance feature differentiating PluroGel® products and giving them important competitive advantage.

“Receiving a new patent that directly covers our advanced PluroGel® Biomaterial products will be an important new strategic asset for the Company adding protection and value for Plurogen and its investors” noted Neal Koller, President and CEO of PluroGen.

For Immediate Release
Contact: Neal Koller
President & CEO
+1 (610) 539‐3670

PluroGen Therapeutics, Inc. Announces Australia Patent Issued For PluroGen’s Advanced PluroGel Biomaterial

Posted on February 19, 2015 by - Uncategorized

Download PDF

2495 General Armistead Avenue ● Norristown, Pennsylvania 19403 ● USA ● Tel: +1 (610) 539-3670 ● Fax: +1 (610) 539-3831

Norristown, Pennsylvania, 1 July 2014

PluroGen Therapeutics, Inc., leading solutions for wound, burn and skin care with its advanced PluroGel® Biomaterial surfactant products, announced today that it received an Australia patent protecting its advanced PluroGel® Biomaterial products. PluroGel® Biomaterial products’ patent protection in Australia is now extended to 2028.

The newly issued Australian patent protects the key properties of biofilm prevention and dispersion for the Company’s advanced PluroGel® Biomaterial products. Biofilm establishment in a wound is thought to prevent wound healing. PluroGel’s ability prevent and disperse biofilms is a significant performance feature differentiating PluroGel® products and giving them important competitive advantage.

“Obtaining patent protection for our PluroGel® Biomaterial products in Australia is an important forward step for the Company and a great addition to our intellectual property portfolio” said Neal Koller, President and CEO of PluroGen. “This new patent is anticipated to anchor our commercialization plan for Australia as we look to enter this market”. About PluroGen Therapeutics

For Immediate Release
Contact: Neal Koller
President & CEO
+1 (610) 539‐3670

PluroGen Therapeutics, Inc. Announces Australia Patent Issued For PluroGen’s Polysaccharide Natural Gel Technology

Posted on February 19, 2015 by - Uncategorized

Download PDF

2495 General Armistead Avenue ● Norristown, Pennsylvania 19403 ● USA ● Tel: +1 (610) 539-3670 ● Fax: +1 (610) 539-3831

Norristown, Pennsylvania, 4 June 2014

PluroGen Therapeutics, Inc., leading solutions for wound, burn and skin care with its advanced PluroGel® Biomaterial surfactant products, announced today that a new patent has been issued by Australia to protect its Polysaccharide Natural Gel Technology. With this patent, PluroGen’s Australia patent protection is extended to 2027.

The Polysaccharide Natural Gel Technology will be used for the Company’s next generation PluroGel® Products, providing clinically important new features for the PluroGel® line. Additionally, the Polysaccharide Natural Gel Technology holds the potential for a new line of products addressing new markets for the Company.

“Obtaining patent protection for our Polysaccharide Natural Gel Technology products in Australia is an important milestone for the Company strengthening our intellectual property portfolio and our future market launch position in the Australian market” commented Neal Koller, PluroGen President & CEO. “Our PluroGel® Products are already achieving superior patient results and adding the properties of the Polysaccharide Natural Gel Technology is expected to give the Company’s products an additional and important edge in the Australian market place.

For Immediate Release
Contact: Neal Koller
President & CEO
+1 (610) 539‐3670

PluroGen Therapeutics, Inc. Announces Its Participation at the European Wound Management Association (EWMA) Conference 2014, 14 to 16 May in Madrid, Spain

Posted on February 19, 2015 by - Uncategorized

Download PDF

2495 General Armistead Avenue ● Norristown, Pennsylvania 19403 ● USA ● Tel: +1 (610) 539-3670 ● Fax: +1 (610) 539-3831

FOR IMMEDIATE RELEASE
Norristown, PA. 7 May, 2014

PluroGen Therapeutics, Inc, an emerging leader in advanced wound care solutions, announced today that it will participate in the European Wound Management Association (EWMA) Conference in Madrid, Spain, May 14 – 16 2014. The conference will be organized in cooperation with Grupo Nacional para el Estudio y Asesoramiento en Úlceras por Presión y Heridas Crónicas (National Advisory Group for the Study of Pressure Ulcers and Chronic Wounds) (GNEAUPP) and Fundación Sergio Juán Jordán para la Investigación y el Estudio de las Heridas Crónicas (Foundation for investigation & study on chronic wounds).

The EWMA Conference offers high level scientific presentations, networking activities and an excellent opportunity to exchange knowledge and experiences with international colleagues. “PluroGen is very pleased with the outstanding patient results our products have provided to Doctors, Nurses and Patients in Europe” said Neal Koller, President and CEO. “PluroGen has expanded its distribution network to include 12 distributors in 14 countries and we are looking forward to continued solid growth and successful patient outcomes in Europe.”

PluroGen representatives will be available throughout the conference for one-on-one meetings with health care professionals at the PluroGen Booth # 10B13. To set up a meeting during the show, please email europe@plurogen.com.

PluroGen to Attend MEDICA Conference November 20-23, 2013 Messe Düsseldorf, Germany

Posted on February 19, 2015 by - Uncategorized

Download PDF

2495 General Armistead Avenue ● Norristown, Pennsylvania 19403 ● USA ● Tel: +1 (610) 539-3670 ● Fax: +1 (610) 539-3831

(Norristown, Pennsylvania, USA, 4 November 2013) – PluroGen Therapeutics, Inc., a leader in advanced wound care solutions, announced today that it will attend MEDICA, the world’s largest medical trade fair on November 20-23, 2013.

This is the second year in a row that PluroGen will be in attendance. PluroGen representatives will be demonstrating the PluroGel® line of burn and wound care products and looking for new distributors, discussing with them how selling the PluroGel® line will differentiate them to increase their sales and profits.. Kati Weiss, PluroGen’s European Manager, will be available throughout the conference for one-on-one meetings at the PluroGen Booth located in Hall 06, Booth G47. To set up a meeting during the show with a PluroGen representative, send an email to europe@plurogen.com.

PluroGen’s primary platform is its core PluroGel® surfactant-based biomaterial that is sharply focused to improve outcomes for patients with burns and chronic (non-healing) wounds. PluroGen currently markets 2 excusive and advantaged medical device barrier products in certain countries in Europe, the Middle East and Africa; PluroGel® Burn and Wound (without antimicrobial) and PluroGel® PSSD (with single antimicrobial for enhanced barrier protection). “PluroGel® is being used in burn and wound centers across Europe with tremendous success.” said Neal Koller, President and CEO of PluroGen. “Our team is very excited about attending the MEDICA Congress again this year. Our goal is to find new partners in new countries who have an interest in the extremely high growth sector of the Advanced Wound Care Market, which is estimated to be $16.8Billion worldwide and growing. We want to educate and update distributors on our exciting new product launch of PluroGel® Burn and Wound as well as continue to tell our story about how our clinically advanced PluroGel® surfactant-based biomaterial can help physicians and healthcare providers make great strides in their burn and wound care challenges. This in turn will help new distributors grow their sales, profits and quality reputation.”

About MEDICA:

MEDICA is the world’s largest medical trade fair and covers the entire spectrum of exhibits for both ambulant and in-patient treatments.

MEDICA will be held at the Messe Düsseldorf in Germany with over 4,500 exhibitors from 70 countries, 17 exhibition halls, 5 exhibition areas, 7 forums and 2 congresses. www.medica tradefair.com.

For Immediate Release
11 November 2013
Contact: Tricia Thompson
Business Development
+1 (610) 539-3670

PluroGen Receives Approval to Sell in France

Posted on February 19, 2015 by - Uncategorized

Download PDF

2495 General Armistead Avenue ● Norristown, Pennsylvania 19403 ● USA ● Tel: +1 (610) 539-3670 ● Fax: +1 (610) 539-3831

(Norristown, Pennsylvania, USA, 31 October 2013) – PluroGen Therapeutics, Inc., a leader in advanced wound care solutions, announced today that it received approval from ANSM, the French Health Authority, to sell its unique and advanced PluroGel® PSSD and PluroGel® Burn and Wound in France.

The Advanced Wound Care Market in France is estimated by the Company to be a $680 million opportunity for PluroGen. While France is part of the European Union participating in the pan-European CE Mark System of medical device approval, France has its own internal system, managed by its national health authority, ANSM, to allow life science products to be sold. ANSM approval to sell is a big step forward for PluroGen, opening the opportunity to enter the French market.

“PluroGen has achieved another important milestone. Our PluroGel® Products are already achieving superior patient results in the USA and a number of countries in Europe compared to the competition. With ANSM approval, we can now begin our search for corporate partners and distributors in France.” commented Neal Koller, President and CEO of PluroGen. “Having France’s ANSM approval adds another valuable asset to the Company, opens another large market opportunity and enhances shareholder value”.

For Immediate Release
31 October 2013
Contact: Tricia Thompson
Business Development
+1 (610) 539-3670

PluroGen Therapeutics, Inc. Enters $126 Million South African Market

Posted on February 19, 2015 by - Uncategorized

Download PDF

2495 General Armistead Avenue ● Norristown, Pennsylvania 19403 ● USA ● Tel: +1 (610) 539-3670 ● Fax: +1 (610) 539-3831

(Norristown, Pennsylvania, USA, 9 October 2013) – PluroGen Therapeutics, Inc., a leader in advanced wound care solutions, announced today that it has entered the South African market with its break-through line of PluroGel® Products, receiving and shipping the 1st order from its new South African distribution partner.

“Entering South Africa opens a terrific market opportunity for PluroGen” commented Neal G. Koller, PluroGen President & CEO. “South Africa is reported to have 52 million people and we estimate the Advanced Wound Care Market, the target market for our PluroGel® Products, could be as much as $126 million annually. Our distribution partner has already initiated relationships with doctors and patients and is working to obtain Regulatory Approval from the South African government. With regulatory approval, the South Africa market provides PluroGen with an excellent opportunity for sales and profit growth.”

For Immediate Release
9 October 2013
Contact: Tricia Thompson
Business Development
+1 (610) 539-3670

PluroGen Therapeutics, Inc. Files Another New Patent Application for its PluroGel® Surfactant Technology

Posted on February 19, 2015 by - Uncategorized

Download PDF

2495 General Armistead Avenue ● Norristown, Pennsylvania 19403 ● USA ● Tel: +1 (610) 539-3670 ● Fax: +1 (610) 539-3831

(Norristown, Pennsylvania, USA, 4 October 2013) – PluroGen Therapeutics, Inc., a leader in advanced wound care solutions, announced today that it filed another new patent application for its PluroGel® Surfactant Technology Product Line. This new patent application is intended to protect the Company’s flagship PluroGel® Product Line in a multibillion segment of the Advanced Wound Care Market.

Commenting on the new patent filing, PluroGen President & CEO, Neal G. Koller, said “This is another milestone achievement for PluroGen. We now have multiple patent applications filed just for our PluroGel® Surfactant Technology. This new application adds to our Intellectual Property Plan which now maps our protection potential to 2033. Each of these patent applications has the possibility to expand protection for the Company’s business and increases shareholder value. With this filing, the opportunity to have product exclusivity in such a large market segment is very exciting.”

For Immediate Release
4 October 2013
Contact: Tricia Thompson
Business Development
+1 (610) 539-3670